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Abstract We constructed a plasmid containing a chimeric gene
composed of the gene encoding acetylcholinesterase (AChE)
from Bungarus fasciatus venom and a gene encoding a single
chain antibody fragment (scFv) directed against one of the two
subunits of a presynaptic neurotoxin from rattlesnake. Large
quantities of the fusion protein were produced in the culture
medium of transfected COS cells. Fusion to AChE did not affect
the ability of the scFv to recognise its antigen. Similarly, the
AChE activity was not impaired in the fusion. The fusion protein
was purified from the culture medium in a single step by affinity
chromatography. The immunoconjugate obtained consisted of a
soluble monomeric form of AChE fused to scFv. It was
monovalent and had a molecular weight of 94 kDa. The
properties of this scFv-AChE fusion show that the simple,
reproducible preparation of various recombinant monovalent
immunoenzymatic tracers with low molecular weight is possible.
In addition, in the construct presented, the scFv domain can be
easily changed to another one taking advantage of the SfiI-NotI
restriction sites surrounding this domain.
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1. Introduction
Immunoenzymatic techniques using solid supports, partic-
ularly enzyme-linked immunosorbent assays (ELISA), are
widely used for the determination in vitro of many biological
substances [1^3]. In principle, numerous enzymes can be used
for producing the immunoenzymatic tracers. Actually, since
the enzyme assay must be simple, sensitive and accurate, the
choice of enzyme is limited. In addition, the enzyme must be
stable in the media containing the samples and must not in-
teract in a non-speci¢c manner with the solid phase or the
proteins present in the sample. The enzyme used must also be
easy to obtain in large quantities and at low cost, to make the
process economically viable. In practice, four enzymes, horse-
radish peroxidase, alkaline phosphatase, L-galactosidase and
acetylcholinesterase (AChE), are commonly used for ELISA
[4,5]. AChE has many advantages over the other enzymes. Its
catalytic constant is higher than those of the other enzymes:
14 000 s31 in comparison to 2000 s31 for alkaline phospha-
tase, 250^500 s31 for L-galactosidase and 1000 s31 for horse-
radish peroxidase [6^8]. Further, assay for AChE activity is
simple, the signal increases linearly with time and there is no
need to stop the reaction, as is necessary for peroxidase or
alkaline phosphatase [9]. This makes it possible to adapt tests
to the concentration of the substance in the sample, simply by
changing the times at which readings are taken. High concen-
trations can be determined rapidly and lower concentrations
after a longer incubation time. AChE has already been used
successfully in ELISA to determine the concentrations of var-
ious substances in homogeneous and heterogeneous phases [9^
13].
The preparation of immunoenzymatic tracers requires cou-
pling an antigen or an immunoglobulin to the enzyme used
for the assay. In almost all cases, this coupling is achieved
chemically and speci¢c protocols, sometimes di⁄cult to re¢ne
and optimise, are required for each tracer. The coupling proc-
ess must be repeated for each batch, and therefore the di¡er-
ent batches will have di¡erent characteristics and have to be
tested. Highly puri¢ed reagents are also required, to ensure
that there is no non-characterised coupling which could lead
to irrelevant results. The construction of fusion genes allowing
the production of recombinant proteins in cell-based systems
is an approach which avoids many of the di⁄culties associ-
ated with the chemical preparation of immunoreactive tracers.
Immunoenzymatic tracers have already been prepared using
these techniques: genes for antibodies of various sizes (Fab or
scFv) have been fused to the gene encoding alkaline phospha-
tase to produce bifunctional conjugates linking an scFv or
Fab with both catalytic subunits of alkaline phosphatase [14].
AChE from the venom of the snake Bungarus fasciatus has
recently been characterised [15^17]. It is a soluble monomeric
protein, in contrast to the other known AChE which are
homo- or hetero-oligomers, soluble or attached to membranes
via glycolipids or structural proteins (dimers and tetramers)
[18,19]. The catalytic constant of AChE of B. fasciatus is low-
er than that of tetrameric AChE from Electrophorus electricus
(7000 s31 for B. fasciatus compared to 14 000 s31 for E. elec-
tricus AChE) but higher than those of horseradish peroxidase
and alkaline phosphatase. The B. fasciatus AChE gene is also
expressed more e⁄ciently by COS cells than AChE genes of
other species [15,19].
In this work, we describe the use of genetic engineering
techniques to produce a fusion protein containing a scFv di-
rected against the CA subunit of crotoxin, the major toxic
protein of the venom of the South-American rattlesnake, Cro-
talus durissus terri¢cus [20] and the monomeric AChE of B.
fasciatus. The fusion between the two proteins does not a¡ect
the catalytic rate of the enzyme or the ability of the scFv to
recognise its antigen. We therefore demonstrate the potential
value of this system for the preparation of monovalent immu-
noenzymatic tracers for ELISA.
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2. Materials and methods
2.1. Materials
Acetylthiocholine and 5,5P-dithio-bis(2-nitrobenzoic acid) were pur-
chased from Sigma (St. Louis, MO, USA). The enzymes used for
plasmid constructions were obtained from Boehringer-Mannheim
(Germany) and Promega Biotech (Madison, WI, USA). Monoclonal
anti-c-myc 9E10 antibody was obtained from Pharmingen (San Diego,
CA, USA). Crotoxin and the CA subunit of crotoxin were puri¢ed
from the venom of C. durissus terri¢cus as previously described
[21,22]. Other reagents and solvents were purchased from Merck
(Darmstadt, Germany), Sigma (St. Louis, MO, USA) or Prolabo
(Paris, France). Microtitration plates were supplied by Nunc (Ros-
kilde, Denmark). VX (O-ethyl-S-[2-(diisopropylamino)ethyl] methyl-
phosphothioate) was a gift of Daniel Froment (Centre d’Etudes du
Bouchet, Vert-le-Petit, France).
2.2. Production of the chimeric gene encoding AChE and scFv
A cDNA encoding the AChE from the venom of B. fasciatus was
isolated from a cDNA library in pT3T7 (Pharmacia), constructed
using the EcoRI and NotI sites [15]. A fragment encoding the catalytic
domain (nucleotides 1^1698) was ligated between the EcoRI and NotI
sites of pCDNA3 (Invitrogen) to give pC-AChE, which was used as a
control [15]. The chimeric gene was produced by PCR, using a primer
with a sequence identical to that of nucleotides 1438^1459 and an
antisense primer complementary to the sequence of the AChE gene
of B. fasciatus (1884^1901), containing the coding sequence for the
c-myc polypeptide and the S¢I restriction site (Fig. 1A). The ampli¢ed
fragment was inserted into pGEM-T (Promega) and sequenced. It was
then ligated between the BglII and NotI sites of pT3T7, downstream
of the cDNA encoding AChE. The BamHI-NotI fragment was re-
moved from this plasmid and ligated into pC-AChE, replacing the
3P fragment of the truncated cDNA, to produce pC-AChE-c-myc.
The gene encoding scFv I12, the antibody fragment speci¢c for the
CA subunit of crotoxin [20], was ligated between the S¢I and NotI
sites of pC-AChE-c-myc to produce pC-AChE-scFv, a plasmid which
thus contains the chimeric gene (Fig. 1B).
2.3. Transfection of COS cells
COS cells were transfected with 5 Wg of pC-AChE-scFv, using the
DEAE-dextran method, as described by Bon and Massoulie¤ [23]. The
cells were then cultured at 37‡C for 5 days and collected by centrifu-
gation (4000 rpm for 10 min). The supernatant was removed and
saved. The cells were suspended in 500 Wl phosphate-bu¡ered saline
(PBS) containing protease inhibitors (Complete, Boehringer) and sub-
jected to sonication for 90 s. Intact cells were pelleted by centrifuga-
tion, and the supernatant (cell extract) was removed and stored at
4‡C.
2.4. Puri¢cation of the fusion protein
The AChE-scFv fusion protein was puri¢ed by a⁄nity chromatog-
raphy, as described by Massoulie¤ and Bon [23]. An a⁄nity gel for
AChE was prepared by coupling the ligand, m-carboxyphenyldime-
thylethyl, to EAH Sepharose 4B [24]. The culture medium of COS
cells (3 ml) was dialysed against 0.1 M potassium phosphate, pH 7.4
(bu¡er I) and added to a column containing 1 ml of the a⁄nity gel,
equilibrated with the same bu¡er. The column was washed with 2 ml
of bu¡er I, then with 2 ml of bu¡er I containing 0.25 M NaCl. It was
then eluted with 2 ml of bu¡er I containing 0.25 M NaCl and 20 mM
decamethonium. The fractions with AChE activity were pooled and
dialysed against 0.05 M potassium phosphate bu¡er, pH 7.4, for 72 h
at 4‡C.
2.5. Measurement of AChE activity
AChE activity was determined by colorimetry with Ellman’s re-
agent [25]. The speci¢c activity was determined as a function of re-
sidual activity after incubation of enzyme with several concentrations
of VX as described previously [15].
2.6. Detection of the fusion protein by ELISA
Microtitration plates were coated by incubation with the CA sub-
unit of crotoxin (100 Wl per well of a 1 Wg/ml solution in PBS) for 2 h
at 37‡C. They were then saturated using 100 Wl per well of 0.1%
Tween 20, 3% bovine serum albumin (BSA) (bu¡er II). Supernatants
from COS cultures and cell extracts were serially diluted in bu¡er II.
100 Wl aliquots of each dilution was added to each well and the plates
were incubated for 1 h at 37‡C. Two detection methods were used.
AChE activity was detected by adding 100 Wl Ellman’s 2Ureagent per
well and incubating for various periods of time. Optical density at
415 nm was then measured. The fusion protein was detected by add-
ing 100 Wl of a 1 in 500 dilution in bu¡er II of monoclonal antibody
9E10, speci¢c for the c-myc polypeptide, to each well and incubating
for 1 h at 37‡C. The plate was washed with PBS containing 20%
Tween 20 (PBS-Tween) and incubated with a peroxidase-conjugated
anti-mouse IgG antibody. The plate was washed again, incubated
with the substrate, o-phenylenediamine (OPD), and optical density
measurements were performed at 490 nm.
2.7. A⁄nity of the fusion protein
The fusion protein, AChE-scFv, was incubated at an appropriate
dilution (as assessed from the direct ELISA experiments) with various
concentrations of the CA subunit, overnight at 4‡C. Aliquots (100 Wl)
were transferred to a microtitration plate coated with CA and incu-
bated for 30 min at 37‡C. The plate was washed with PBS-Tween and
residual AChE activity was determined as described above, after in-
cubation of the plate for 4 h at 37‡C.
Fig. 1. Construction of the AChE-scFv conjugate. A: Oligonucleotide used to produce the chimeric gene. B: Construct transfected in COS
cells. pC-AChE-scFv encodes a fusion protein associating B. fasciatus AChE with a scFv anti-CA. These domains are separated by a c-myc
peptide. The pC-AChE construct encodes AChE restricted to the catalytic domain and was used as a control.
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2.8. Analysis of the fusion protein by polyacrylamide gel electrophoresis
(PAGE)
The solution containing the a⁄nity-puri¢ed protein was concen-
trated by centrifugation on a Centricon slide (Amicon, Grasse,
France) and subjected to SDS-PAGE in a 12.5% acrylamide gel
with a Phastsystem apparatus (Pharmacia, Uppsala, Sweden). The
gel was stained using the colloidal Coomassie kit (Novex, San Diego,
CA, USA).
3. Results
3.1. Construct encoding the AChE-scFv fusion protein and
expression in COS cells
A scheme of the synthetic gene construct encoding the
AChE-scFv fusion protein is shown in Fig. 1B. B. fasciatus
AChE undergoes a post-translational cleavage removing the
last eight residues before secretion by COS cells. For this
reason, the AChE domain of the fusion protein is restricted
to the catalytic domain and ends seven amino acids upstream
of the cleavage site. The c-myc domain is recognised by the
9E10 antibody, facilitating the detection of the fusion protein.
The scFv domain encodes an antibody that recognises the CA
subunit of crotoxin [20]. The scFv domain is inserted between
S¢I-NotI restriction sites. This allows an easy change of this
domain and the use of this construct with virtually any cloned
scFv.
The production of the AChE-scFv fusion protein by trans-
fected COS cells was checked by measuring AChE activity in
the culture medium and in cell extracts obtained by sonication
of the cells (Table 1). We used pC-AChE as a positive control
and pCDNA3 with no insert as a negative control for the
transfection of COS cells. Low levels of AChE activity were
detected in the supernatants of cells transfected with the vec-
tor lacking an insert, presumably due to the secretion of the
native AChE of COS cells or to the AChE activity of the
serum used for the cell growth and remaining in the trans-
fection medium. Higher levels of AChE activity were detected
in cells transfected with pC-AChE-scFv or pC-AChE.
3.2. Functional properties of the AChE-scFv fusion protein
The AChE-scFv fusion protein was detected in cell extracts
by ELISA. The microtitration plate was coated with the CA
subunit and anti-c-myc antibody 9E10 was used for detection
(Fig. 2A). The negative control was supernatant of cells trans-
fected with pC-AChE and disrupted by sonication. A protein
containing scFv and the c-myc peptide was clearly present in
the culture medium of COS cells transfected with pC-AChE-
scFv. No such protein was detected on the supernatant of cells
transfected with pC-AChE. Similar results were obtained us-
ing culture supernatants of transfected COS cells (results not
shown).
The fusion protein was also detected using an alternative
ELISA test in which the microtitration plate was coated with
the CA subunit and the protein was detected by direct meas-
urement of AChE activity. The fusion protein was speci¢cally
detected in COS cells transfected with pC-AChE-scFv, even at
a dilution of the conjugate as high as 1 in 2000 (Fig. 2B). This
detection method was much more sensitive than detection
with the anti-c-myc antibody which can only detect the con-
jugate in dilutions of 1 in 180 or lower (Fig. 2A). Thus, the
AChE activity measured was associated with scFv, which rec-
ognised the CA subunit bound to the microtitration plate.
AChE activity as determined by these ELISA assays was in-
hibited in a dose-dependent manner by the CA subunit, with
50% inhibition at a CA subunit concentration of 5U1039 M
(Fig. 3). The IC50 of CA in the AChE-scFv complex was
identical to the a⁄nity of the parental antibody, A-56.36,
for CA and that of free scFv [20,26]. This shows that the
a⁄nity of scFv I12 for CA was not a¡ected by fusion to
AChE. The catalytic properties of B. fasciatus AChE do not
seem to be modi¢ed by the association of this enzyme with a
scFv since the turnover number of the immunoenzymatic trac-
Table 1
AChE activity measurement in COS cell extracts and culture super-
natants
Vector Enzymatic activity
(U/ml)
Deduced concentration
(Wg/ml)
Cell extracts
pCDNA3 8.5 þ 1.14 0.112 þ 0.015
pCB1 30.3 þ 4.36 0.401 þ 0.057
pC-AChE-scFv 74.56 þ 7.14 0.985 þ 0.09
Culture supernatants
pCDNA3 0.03 þ 0.005 0.44U1033
pcB1 52.2 þ 0.07 0.691 þ 0.0009
pC-AChE-scFv 102.1 þ 0.014 1.36 þ 0.00018
Fig. 2. Function of the immunoenzymatic tracer, AChE-scFv. Cul-
ture medium was incubated in a microtitration plate coated with the
CA subunit as described in Section 2. The conjugate was revealed
by 9E10 anti-c-myc antibody (A) or directly by AChE activity (B).
(a) pC-AchE; (E) pC-AChE-scFv. To allow comparison, the
amount of conjugate was normalised according to AChE activity.
Note that the scale of each graph is di¡erent.
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er is identical to that of recombinant AChE, 6700 þ 30 s31
(n = 3) compared to 6600 þ 80 s31, respectively.
3.3. Puri¢cation of the AChE-scFv fusion protein and PAGE
analysis
We puri¢ed the AChE-scFv fusion protein from the cell
culture supernatants of COS cells transfected with pC-
AChE-scFv in a single step, by AChE a⁄nity chromatogra-
phy. The puri¢cation yield was 40%. The puri¢ed fraction
gave a single protein band in SDS-PAGE, showing that the
fusion protein can be e¡ectively and simply puri¢ed from cell
culture medium (Fig. 4). The estimated molecular weight of
this protein was slightly higher than 94 kDa, consistent with
the molecular weight of the fusion protein (97 kDa) calculated
from the molecular weight of its components, scFv I12 (25
kDa) and AChE (72 kDa).
4. Discussion
We produced a fusion protein containing the AChE of B.
fasciatus linked by a c-myc peptide to an scFv which recog-
nises the CA subunit of crotoxin. This fusion protein was
e⁄ciently secreted in the culture medium by transfected
COS cells. The fusion protein was active: via scFv it binds
speci¢cally to the CA subunit coated onto microtitration
plates and is detected by measuring AChE activity. Fusion
of scFv to AChE did not a¡ect its ability to recognise the
antigen, because the a⁄nity of the fusion protein (5U1039
M) is similar to that previously determined for scFv and the
parental immunoglobulin [26,20]. Ducancel et al. [14] ob-
tained a fusion protein containing an scFv derived from a
monoclonal antibody against the K toxin of Naja nigricollis
venom linked to Escherichia coli alkaline phosphatase in a
bacterial system. However, they found that fusion of the
scFv to alkaline phosphatase caused a moderate but signi¢-
cant reduction of the a⁄nity of the scFv for its antigen. The
catalysis rate of the fusion protein was not modi¢ed when
compared with that of AChE extracted from venom (or con-
trol recombinant AChE), furthermore, the fusion protein is
readily puri¢ed from culture supernatants of transfected
COS cells by a⁄nity chromatography using an AChE ligand.
The immunoconjugate produced in this study comprises a
soluble monomeric form of AChE and an scFv. It was mono-
valent and had a molecular weight of less than 100 kDa. It
has therefore a di¡erent structure than the alkaline phospha-
tase/anti-K-toxin scFv immunoconjugate synthesised by Du-
cancel et al. [14], which was bifunctional, containing a dimeric
alkaline phosphatase associating two scFv molecules. In many
circumstances, a monovalent immunoconjugate with a lower
molecular weight should be more useful and more e¡ective
than a bivalent immunoconjugate of higher molecular weight.
It should di¡use and bind to the antigen more rapidly and the
presence of only one binding site per conjugate should prevent
the formation of complexes when several antigen sites are
present in a single structure. This reduces the risk of non-
speci¢c interactions.
The AChE of B. fasciatus is much more highly expressed
than those of other species by transfected COS cells [15^19]
and other eukaryotic expression systems [27]. The fusion pro-
tein was produced in large quantities and its concentration in
the culture medium of transfected COS cells was about 1 Wg/
ml. The AChE-scFv immunoconjugate was produced and se-
creted by the COS cells in an active form that is readily and
e⁄ciently puri¢ed in a single step using cheap, reusable, a⁄n-
ity columns. This is more satisfactory than the procedure de-
scribed by Ducancel et al. [14], where the alkaline phospha-
tase/scFv fusion protein precipitated in the cytoplasm of the
bacteria and has to be renatured and puri¢ed by less e⁄cient
classical methods. However, their method nevertheless al-
lowed the production of a useful recombinant tracer in sig-
ni¢cant amount, suggesting that even better results could be
obtained with more e⁄cient expression systems than COS
cells, such as those involving yeasts or insect cells.
The method we have developed for the preparation of an
immunoenzymatic tracer for detection of the CA subunit of
crotoxin could be used for other molecules. It is based on the
use of genetic engineering to produce a fusion protein con-
taining the soluble, monomeric AChE from B. fasciatus and a
scFv. This protocol could be adapted to the production of
other immunoenzymatic tracers, so long as the speci¢c scFv
Fig. 3. A⁄nity of the fusion protein, AChE-scFv, for the CA sub-
unit. Culture medium from COS cells transfected with the chimeric
gene was diluted 1 in 800 and incubated overnight at 4‡C with vari-
ous concentrations of the CA subunit. AChE activity was measured
using the method of Ellman.
Fig. 4. Electrophoresis of the a⁄nity-puri¢ed fusion protein. Dena-
tured proteins in 1% SDS, 0.1 M L-mercaptoethanol were loaded
onto a 12.5% polyacrylamide gel and subjected to electrophoresis.
The gel was stained with Coomassie blue. The molecular weight
markers are indicated by an arrow (phosphorylase b, 94 kDa; BSA,
67 kDa, ovalbumin, 43 kDa; carbonic anhydrase, 30 kDa, trypsin
inhibitor, 20 kDa); lane 1: AChE from B. fasciatus venom, puri¢ed
by a⁄nity chromatography; lane 2: AChE-scFv fusion protein puri-
¢ed by a⁄nity chromatography.
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required has been cloned using S¢I and NotI sites. The B.
fasciatus AChE in the N-terminal part of our fusion has
very high activity, and this would presumably also be the
case in any other analogous fusions. Moreover, it is straight-
forward to obtain highly pure preparations of this type of
immunoenzymatic tracer by a⁄nity chromatography. The
production of conjugate could probably be improved by es-
tablishment of stable cell lines.
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